Clinical Trial Update: Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating arformoterol for bronchoprotective effect in children with exercise-induced bronchospasm has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exercise-induced Bronchospasm

Drugs mentioned

• Brovana (arformoterol)

Snippet

Sponsor: University of New Mexico | Conditions: Exercise-induced Bronchospasm | Phase 3 | Status: WITHDRAWN